Clinical Trials
88 trialsT Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Astellas Pharma Inc
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
TRIDENT-1
Turning Point Therapeutics, Inc.
TROPION-Lung12
AstraZeneca
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
VISION
EMD Serono
AcceleRET-Lung
Hoffmann-La Roche
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
FIRSTLUNG
Delfi Diagnostics Inc.
Treatment of Multifocal Lung Adenocarcinoma
Mayo Clinic
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
Bristol-Myers Squibb
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
Novartis
ARROW
Hoffmann-La Roche
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Immuneering Corporation
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
A Study of NDI 1150-101 in Patients With Solid Tumors
Nimbus Therapeutics
KEYNOTE-782
Merck Sharp & Dohme LLC
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Icahn School of Medicine at Mount Sinai
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Morphotek
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
AO GENERIUM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Mural Oncology, Inc
SELECT-2
Hangzhou Normal University
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Checkpoint Therapeutics, Inc.
EUCROSS
University of Cologne
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Novartis
SHERLOC
Elevation Oncology
ALTA-1L
Takeda
APICAL
Chonnam National University Hospital
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Endocyte
TARGET
Endocyte
MK-6018-001
KitovPharma
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Acrotech Biopharma Inc.
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Dana-Farber Cancer Institute
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center